Company Overview and News

 
Rox releases nickel study

2018-10-10 businessnews.com.au
Rox Resources has released an updated scoping study for its Fisher East nickel project following an improvement in market conditions, with a forecast capital cost of between $85 million and $125 million.
RXL RXXRF

 
Rox Resources to acquire Bronzewing South Gold Project in WA

2018-08-08 proactiveinvestors.com.au
Rox Resources Ltd (ASX:RXL) has acquired an option to purchase the Bronzewing South Gold Project in Western Australia from private company Carnegie Exploration Pty Ltd.
RXL EAR RXXRF

13
Rox targets improving nickel market

2018-05-23 australianmining.com.au
Rox Resources has been busy since winning Explorer of the Year at the 2015 Australian Mining Prospect Awards.
RXL RXXRF MZN FCN TCKRF TECK

 
Rox Resources establishing gold subsidiary and strategically focusing on nickel

2018-05-16 proactiveinvestors.com.au
Rox Resources Ltd (ASX:RXL) managing director Ian Mulholland speaks to Proactive Investors about the exploration company’s strategic pivot to nickel, and plans to spin out its West Australian Mt Fisher Gold Project into a 100%-owned subsidiary, to be named Helios Gold Limited and floated on the Australian Stock Exchange.
RXL RXXRF SABR

 
Rox unveils new spin-off Helios Gold for Mt Fisher project

2018-05-08 australianmining.com.au
Rox Resources plans to create a new subsidiary called Helios Gold to oversee operations at its Mt Fisher gold project in Western Australia. Rox intends to list Helios publicly on the ASX via an initial public offering (IPO).
RXL RXXRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:RXL / ROX RESOURCES LIMITED on message board site Silicon Investor.

Crucell N.V. (CRXL) Crucell N.V. (CRXL) Crucell N.V. (CRXL) PRXL - Parexel International PRXL - Parexel International PRXL - Parexel International